29 September 2009
immatics appoints Carsten Reinhardt as Chief Medical Officer ... more» (WEB)
10 August 2009
immatics obtains further important EP patents covering its lead product IMA901 and US patent for MUC-1 peptide ... more» (PDF)
17 June 2009
immatics biotechnologies significantly improves XPRESIDENT™ technology platform ... more» (PDF)
02 March 2009
immatics completes patient recruitment in phase II study with cancer vaccine IMA901 for renal cell cancer ... more» (PDF)
26 January 2009
immatics wins 29th German Industry’s Innovation Award ... more» (PDF)
immatics appoints Carsten Reinhardt as Chief Medical Officer ... more» (WEB)
10 August 2009
immatics obtains further important EP patents covering its lead product IMA901 and US patent for MUC-1 peptide ... more» (PDF)
17 June 2009
immatics biotechnologies significantly improves XPRESIDENT™ technology platform ... more» (PDF)
02 March 2009
immatics completes patient recruitment in phase II study with cancer vaccine IMA901 for renal cell cancer ... more» (PDF)
26 January 2009
immatics wins 29th German Industry’s Innovation Award ... more» (PDF)
